M4 Allosteric Modulators for Selective Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic agonists, such as xanomeline, face challenges due to lack of adequate receptor subtype selectivity, leading to dose-limiting side effects like gastrointestinal disturbances, bradycardia, nausea, and vomiting.
Innovation Solution
Development of selective M4 positive allosteric modulators (PAMs) that selectively activate the M4 muscarinic acetylcholine receptor, thereby overcoming the limitations of orthosteric agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective muscarinic agonists are used to activate mAChRs, then pro-cognitive and antipsychotic efficacy is achieved, but dose-limiting side effects occur due to lack of receptor subtype selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (pyrazol-4-yl-pyridine core with particular substituents) that confer selective affinity for M4 receptors over other muscarinic subtypes. This structural differentiation enables the drug to target specifically the M4 receptor location and properties, achieving therapeutic effects while avoiding side effects associated with nonselective activation of M1-M5 receptors
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituents R1-R7, X, Y, Z groups) to optimize the balance between M4 selectivity and therapeutic activity. By adjusting these chemical parameters, the compounds achieve enhanced M4 receptor affinity and selectivity compared to nonselective agonists, thereby improving the therapeutic index
2Reliability
If selective M4 positive allosteric modulators are developed, then receptor subtype selectivity is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core pyrazol-4-yl-pyridine scaffold and separate substituent groups (R1-R7, X, Y, Z). This modular segmentation allows independent optimization of each segment for M4 selectivity while maintaining overall structural manageability and facilitating systematic structure-activity relationship studies
Data Source
AI summary
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.